News & articles

This spring allergy season, if you suffer from the distraction and annoyance of itchy eyes or nose, imagine that intense itch across your entire body – every day of the year. That’s what many people living with polycythemia vera (PV) and other MPNs experience. Severe, recurrent MPN-related pruritus (the condition of itching) can have a… Read More »Severe Itching Remains an MPN Research Challenge

The transformation of MPNs to blast-phase (BP) is generally associated with poorer long-term survival. A recently published study in Blood Advances looked at outcomes of intensive and non-intensive blast reduction strategies in both the blast phase and accelerated phase of MPNs. Blasts are immature white blood cells found naturally in the bone marrow and circulating… Read More »Reducing Blasts in MPNs

Profile: Belinda Guo, PhD, University of Western Australia One of the impacts MPNRF has on the global MPN community is the support of researchers whose work in other hematologic areas brings different approaches and potential new findings to the study of MPNs. That was true of Dr. Belinda Guo when she received her first funding… Read More »Belinda Guo

Today, it is essential for patients to be involved with research and drug developers as they progress through the various stages of bringing a new therapy to market. MPN Research Foundation (MPNRF) is committed to ensuring that patient participation is more than a ticked box for drug approval. We actively work to incorporate the patient… Read More »Patients and Caregivers Play an Active Role in MPN Research

Several studies have confirmed the association of ruxolitinib (a JAK inhibitor) with increased risk of non-melanoma skin cancers (NMSCs). A study published in a January 2024 issue of the journal Blood reports on just how serious the risks might be, specifically among patients living with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). And… Read More »UK Study Details Skin Cancer Risks for MPN Patients

  Jyoti Nangalia, MBBS, PhDWellcome Sanger Institute It is known that JAK2 mutations are found in “healthy” people around the world, particularly in older individuals. Most of them don’t acquire characteristics of myeloproliferative neoplasms (MPNs). The question is why do some people with the mutation develop an MPN while others don’t. Researchers from the Wellcome… Read More »Understanding who develops which MPN and why

Cancer is such a powerful word that it is often referred to as “The Big C” and comes with a loaded associated vocabulary, including words that can have both empowering or disturbing triggers, depending on the individual hearing it.   Not many people go through life without being touched by cancer in some way. This means… Read More »Cancer words matter

While cardiovascular events often accompany MPNs and contribute significantly to morbidity and mortality, the reasons remained unclear until research offered some insight in recent years.  Greater understanding about why and how blood cancers have connections to cardiovascular complications lays the groundwork to using this information to better assess and manage risk factors in MPN patients,… Read More »Cardiovascular Risk and MPNs

Thrive Award Spotlight: John Crispino, St. Jude Children’s Research HospitalCo-PI – Ayalew Tefferi, Mayo Clinic, MN Aberrant Megakaryopoiesis in the MPNs According to Leukemia & Lymphoma Society, although MPN patients can be stable for decades, they face a significant risk of having their disease advance to a more immediately life-threatening blood cancer, acute myeloid leukemia… Read More »How MPNs progress to AML and how to stop it

Kyle Bonder                                                                                                           … Read More »Caregiver Brings Unique Perspective to MPNRF Patient Impact Council